Notice: This company has been marked as potentially delisted and may not be actively trading. Chiasma (CHMA) News Today Add Compare Share Share Headlines Stock Analysis All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Chiasma Craters on FDA Drug RejectionOctober 29, 2023 | thestreet.comOrphan Drugs Market Size to Hit USD 340.84 Billion by 2027 - GlobeNewswireOctober 6, 2022 | globenewswire.comIronshore Announces Executive Appointments and Strengthening of the Global Business Management Team - Business WireSeptember 28, 2022 | businesswire.comCHMP adopts positive opinion for Mycapssa® for the treatment of Acromegaly - Marketscreener.comSeptember 16, 2022 | marketscreener.comAmryt (AMYT) Receives Positive CHMP Opinion for Mycapssa - StreetInsider.comSeptember 16, 2022 | streetinsider.comAmryt to Present Data from MPOWERED Phase 3 Trial of Mycapssa® (oral octreotide) at ENEA 2022 - Yahoo Finance UKSeptember 7, 2022 | uk.finance.yahoo.comMPM ASSET MANAGEMENT LLC Buys - GuruFocus.comAugust 12, 2022 | gurufocus.comAmryt Reports Record Q2 2022 Results - GlobeNewswireAugust 4, 2022 | globenewswire.comSpyBiotech Appoints Seasoned Biotech Executive Mark Leuchtenberger as Chief Executive Officer - Business WireJuly 12, 2022 | businesswire.comSpyBiotech Appoints Seasoned Biotech Executive Mark Leuchtenberger as Chief Executive Officer - Yahoo FinanceJuly 12, 2022 | finance.yahoo.comGlobal Food Allergy Pipeline Insight | Clinical Trials Evaluation Research Report 2022 by DelveInsight - Yahoo FinanceJune 20, 2022 | finance.yahoo.comAmryt to Present Data from OPTIMAL and MPOWERED Phase 3 Trials Open Label Extension of Mycapssa® (oral octreotide) at ENDO 2022 - GuruFocus.comJune 18, 2022 | gurufocus.comAt 10.4% CAGR, Global Oral Proteins and Peptides Market Size & Share to Surpass USD 8.42 Billion by 2028 | Industry Trends, Growth, Value, Opportunities, Statistics, Analysis & Forecast Report by Zion Market Research - Yahoo FinanceJune 16, 2022 | finance.yahoo.comThe oral proteins and peptides market is anticipated to grow at a CAGR of 20%, during 2022-2032, claims Roots Analysis - GlobeNewswireJune 15, 2022 | globenewswire.comThe oral proteins and peptides market is anticipated to grow at a CAGR of 20%, during 2022-2032, claims Roots Analysis - Yahoo FinanceJune 15, 2022 | finance.yahoo.comAmryt to Present Data from OPTIMAL and MPOWERED Phase 3 Trials Open Label Extension of Mycapssa® (oral octreotide) at ENDO 2022 - Yahoo FinanceJune 8, 2022 | finance.yahoo.comTop 5 1st Quarter Trades of MPM ASSET MANAGEMENT LLC - GuruFocus.comMay 13, 2022 | gurufocus.comAmryt Reports Record Q1 2022 Results - Financial PostMay 6, 2022 | financialpost.comAmryt Reports Record Q1 2022 Results - GlobeNewswireMay 4, 2022 | globenewswire.com2022-05-04 | NDAQ:AMYT | Press Release | Amryt Pharma plc - StockhouseMay 4, 2022 | stockhouse.comInsights on the Oral Proteins and Peptides Global Market to 2032 - Key Drivers and Challenges - Benzinga - BenzingaMarch 21, 2022 | benzinga.comGlobal Oral Proteins and Peptides Market to 2032 - by - GlobeNewswireMarch 16, 2022 | globenewswire.comAmryt (AMYT) Reports FY Revenues of $222.5M, Growth of 22% - StreetInsider.comMarch 11, 2022 | streetinsider.comAmryt Announces 22% growth in FY 2021 Revenues to $222.5M - GlobeNewswireMarch 9, 2022 | globenewswire.comWarm Autoimmune Hemolytic Anemia Market is Expected to Witness Growth at an Accelerated CAGR of 14.7% in the 7MM for the Study Period 2018-30, Assesses DelveInsight - PRNewswireFebruary 28, 2022 | prnewswire.comGlobal Thermostable Vaccines and Thermostable Biologics Market to 2035 - by Type of Molecule, Target Indications, Type of Therapy, Key Players and Region - ResearchAndMarkets.com - Business WireFebruary 8, 2022 | businesswire.comFood Allergy Market Anticipated to Witness Massive Growth with a Tremendous CAGR of 13.5% in the 7MM for the Study Period of 2018-30 | DelveInsight - PRNewswireJanuary 31, 2022 | prnewswire.comForm 424B3 Amryt Pharma plc - StreetInsider.comJanuary 31, 2022 | streetinsider.comAmryt Announces Positive Long-Term Safety and Efficacy Data confirming the role for Mycapssa® (oral octreotide) in the management of Acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide - Financial PostJanuary 12, 2022 | financialpost.comIN BRIEF: Amryt Pharma delists from AIM as trading shifts to New York - MorningstarJanuary 11, 2022 | morningstar.co.ukVaccine mandates, inflation and remote workforces—here’s what mattered to CFOs this week - FortuneJanuary 7, 2022 | fortune.comThe Lancet Diabetes & Endocrinology Publishes Positive Results for the MPOWERED Phase 3 Trial for Mycapssa® (oral octreotide) in Acromegaly Patients - StockhouseJanuary 5, 2022 | stockhouse.com4D pharma appoints John Doyle as Chief Financial Officer - StreetInsider.comJanuary 5, 2022 | streetinsider.comAre you prepared for what the Supreme Court has to say on vaccine mandates? - FortuneJanuary 4, 2022 | fortune.comThe Lancet Diabetes & Endocrinology Publishes Positive Results for the MPOWERED Phase 3 Trial for Mycapssa® (oral octreotide) in Acromegaly Patients - Yahoo FinanceJanuary 4, 2022 | finance.yahoo.comTBJ Plus: New CEO takes helm for Aerie Pharmaceuticals; $1.5B Novartis deal has Durham link; Thermo Fisher name rises in Wilmington - Triangle Business Journal - Triangle Business JournalDecember 24, 2021 | bizjournals.comVersantis Appoints Mark Fitzpatrick, Seasoned Biotech Executive, as its New CEO - Yahoo FinanceDecember 22, 2021 | finance.yahoo.comNeuroSense: Advancing Generic Combos In Neurodegenerative Diseases - Seeking AlphaDecember 22, 2021 | seekingalpha.comVenatorx Pharmaceuticals Names Scott McConnell, Pharm.D. as Vice President, Medical Affairs - StreetInsider.comDecember 4, 2021 | streetinsider.comVenatorx Pharmaceuticals Names Scott McConnell, Pharm.D. as Vice President, Medical Affairs - Business WireDecember 2, 2021 | businesswire.comCatamaran Bio Announces Appointment of Tara Place as Vice President, Human Resources and Organizational Effectiveness - Yahoo FinanceNovember 15, 2021 | finance.yahoo.comAmryt Pharma (AMYT) CEO Dr. Joe Wiley on Q3 2021 Results - Earnings Call Transcript - Seeking AlphaNovember 7, 2021 | seekingalpha.comAmryt Reports Strong Q3 2021 Results - GlobeNewswireNovember 3, 2021 | globenewswire.comAmryt Reports Strong Q3 2021 Results - Form 6-K - Marketscreener.comNovember 3, 2021 | marketscreener.comAmryt Reports Strong Q3 2021 Results - Yahoo FinanceNovember 3, 2021 | finance.yahoo.comNeuroSense Therapeutics announces the appointment of Mark Leuchtenberger as Chairman of the Board - Yahoo FinanceSeptember 29, 2021 | finance.yahoo.comIN BRIEF: Amryt Pharma ups guidance again after Chiasma acquisition - MorningstarSeptember 14, 2021 | morningstar.co.ukIN BRIEF: Amryt Pharma ups guidance again after Chiasma acquisition | Financial News - London South EastSeptember 14, 2021 | lse.co.ukAmryt Pharma Raises 2021 Revenue Guidance - MarketWatchSeptember 13, 2021 | marketwatch.comAmryt Raises Full Year 2021 Revenue Guidance to $220M - $225M - Yahoo FinanceSeptember 13, 2021 | finance.yahoo.com Get Chiasma News Delivered to You Automatically Sign up to receive the latest news and ratings for CHMA and its competitors with MarketBeat's FREE daily newsletter. Email Address 625,000% Gain (Ad)Imagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz. >> Dive into the Workshop Here CHMA Media Mentions By Week CHMA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CHMA News Sentiment▼0.460.43▲Average Medical News Sentiment CHMA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CHMA Articles This Week▼00▲CHMA Articles Average Week Get Chiasma News Delivered to You Automatically Sign up to receive the latest news and ratings for CHMA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies OptiNose News Xeris Biopharma News Liquidia News AnaptysBio News AbCellera Biologics News Dianthus Therapeutics News Annexon News Pacira BioSciences News Erasca News 89bio News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CHMA) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredNvidia warning urgentI thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredNothing can stop this gold rallyAfter what's felt like nearly a decade of disappointing gains, gold is stronger than ever and continues to hit...Stansberry Research | SponsoredWall St. Legend: Millions of Americans About to Fall Out of the 1%Wall Street insider reveals the financial tidal wave about to knock millions of Americans out of the One Perce...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Chiasma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Chiasma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
